iPS Cells & Regenerative Medicine– category –
-
Streamlining PBMC Processing in Multi-Site Clinical Trials Bridges Translational Gap in Drug Discovery
REPROCELL Blog Japan Overview Efficient processing of peripheral blood mononuclear cells (PBMCs) in multi-site clinical trials is crucial for bridging the translational gap in drug discovery. This article identifies key challenges and pr... -
CRISPR Gene Editing Advances in 2026: Accumulation of Clinical Data and Evolving Regulatory Framework for Rare Diseases, Cancer, and Autoimmune Disorders
Industry report / Analysis USA Overview The CRISPR gene editing landscape in 2026 shows significant progress across rare diseases, hematologic and solid cancers, and autoimmune disorders. Clinical programs are generating crucial data, wh... -
Beam Therapeutics Receives U.S. FDA IND Clearance for BEAM-304, a Base Editing Therapy for Phenylketonuria (PKU)
Beam Therapeutics USA Overview Beam Therapeutics announced U.S. FDA Investigational New Drug (IND) clearance for BEAM-304, its investigational base editing therapy for Phenylketonuria (PKU). This milestone paves the way for human clinica... -
CRISPR Therapeutics Stock Volatility Driven by CASGEVY Commercialization and CTX112 Clinical Progress
Investing.com USA Overview CRISPR Therapeutics has experienced significant stock volatility due to market reactions to the commercialization of its approved CRISPR gene therapy, CASGEVY, and clinical developments for its off-the-shelf CA... -
iPS Cells & Regenerative Medicine Weekly Report May 20, 2026
▼ ▼ ▼ If you found the infographic compelling and want to read the full Weekly Report, click below to download the Strategy Report. ▼ ▼ ▼ 📄 iPS Cells & Regenerative Medicine Weekly Report — June 20, 2026 iPS_RegenerativeMedicine_WeeklyR... -
Cell and Gene Therapy’s Next Frontier: Overcoming Manufacturing, Commercial, and Clinical Infrastructure Challenges Beyond Scientific Discovery
Drug Discovery News USA Overview The primary challenge for cell and gene therapies is shifting from scientific discovery to building robust manufacturing, commercial, and clinical infrastructure. Issues like insufficient durability due t... -
Medyra Health Bolsters Therapeutic Development and Evaluation by Leveraging Real-World Evidence (RWE)
Medyra Health USA Overview Medyra Health outlines its RWE-focused therapeutic approach, emphasizing the generation of high-quality real-world evidence to enhance therapy evaluation and development. The company specializes in RWE study de... -
Orca Bio Expands East Coast Manufacturing Capacity and Triples West Coast Workforce Ahead of Potential Orca-T® Commercial Launch, with FDA PDUFA Date Set for July 6, 2026
Business Wire USA Overview Orca Bio announced significant manufacturing expansions for its investigational cell therapy, Orca-T®, in anticipation of its commercial launch. This includes establishing new East Coast manufacturing capacity ... -
Penn Medicine Leads Cell and Gene Therapy Field, Pioneering Foundational Research for CAR T-Cell Therapies
Penn Medicine USA Overview Penn Medicine highlights its profound expertise in cell and gene therapies, including its foundational work in CAR T-cell therapy. The institution explains how these "biologics" target the root cause of illness... -
Alliance for Cancer Gene Therapy Appoints Jonathan S. Doctor and John Neamonitis to Board of Directors, Strengthening Research Funding Mission
PR Newswire USA Overview The Alliance for Cancer Gene Therapy (ACGT) announced the appointment of Jonathan S. Doctor and John Neamonitis to its Board of Directors. ACGT is a non-profit organization dedicated exclusively to funding scient...
